Rituximab for treatment of ocular inflammatory disease: A series of four cases

British Journal of Ophthalmology

Volumn 93, Issue 4, 2009, Pages 546-548

  Kurz, P A ^a,b,c   Suhler, E B ^a   Choi, D ^a   Rosenbaum, J T ^a,d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d Mail Code L467AD ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPHENHYDRAMINE; ETANERCEPT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; LORAZEPAM; METHOTREXATE; METHYLPREDNISOLONE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PETHIDINE; PREDNISONE; PROMETHAZINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ANGIONEUROTIC EDEMA; ANXIETY; ARTICLE; BRONCHOSPASM; CARDIOGENIC SHOCK; CASE REPORT; CHILL; DEATH; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; EYE INFLAMMATION; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HEPATITIS B; HEPATITIS B REACTIVATION; HUMAN; HYPOTENSION; HYPOXIA; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; LEUKOENCEPHALOPATHY; LOW DRUG DOSE; LUNG INFILTRATE; MALE; MULTIPLE CYCLE TREATMENT; NASAL CRUSTING; NAUSEA; NOSE DISEASE; OPPORTUNISTIC INFECTION; ORBITAL INFLAMMATION; PILOT STUDY; PRIORITY JOURNAL; PRURITUS; RIGOR; SCLERITIS; SIDE EFFECT; SKIN MANIFESTATION; TREATMENT RESPONSE; URTICARIA; WEGENER GRANULOMATOSIS; WEIGHT GAIN;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; ORBITAL DISEASES; PREDNISONE; SCLERITIS; TREATMENT OUTCOME;

EID: 64749117073     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2007.133173     Document Type: Article

References (10)

1. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase l/ll dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580- 9.
2. Keogh KA, Wylam ME, Stone JH, et al. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibodyassociated vasculitis. Arthritis Rheum 2005;52:262-8.
3. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. New England J of Medicine 2004;350:2572-81.
4. Keogh KA, Ytterberg SR, Fervenza FC, et al. Rituximab for refractory Wegener's granulomatosis report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006;173:180-7.
5. El Fassi D, Neilsen CH, Bonnema SJ, et al. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study. J Clin Endocrinol Metab 2007;92:1620-2.
6. El Fassi D, Nielsen CH, Hasselbalch HC, et al. Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid 2006;16:709-10.
7. Salvi M, Vannucchi G, Campi I, et al. Efficacy of rituximab treatment for thyroidassociated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur J Endocrinol 2006;154:511-17.
8. Vannucchi G, Campi I, Curro N, et al. Rituximab treatment of Graves' disease and thyroid-associated ophthalmopathy: effects on thyroid autoimmunity and thyroid morphology at ultrasound. In Proceedings of the 31st Annual Meeting of the European Thyroid Association, Naples, Italy, 2006:20 (Abstract).
9. Tappeiner C, Heinz C, Specker C, et al. Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Res 2007;39:184-6.
10. Popa C, Leandro MJ, Cambridge G, et al. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 years. Rheumatology 2007;46:626-30.